Drug intelligence / Profile preview

bevacizumab + cyclophosphamide + doxorubicin + nab-paclitaxel

Development stage: Phase 2
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of bevacizumab (a monoclonal antibody targeting VEGF), cyclophosphamide and doxorubicin (often given together as "AC" regimen), and nab-paclitaxel (a nanoparticle albumin-bound formulation of paclitaxel). This regimen has been studied primarily as neoadjuvant therapy for locally advanced breast cancer and inflammatory breast cancer, with clinical trials showing improved pathologic complete response rates, particularly in triple-negative breast cancer.

Targets

DNATOP2A (DNA topoisomerase II)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on bevacizumab + cyclophosphamide + doxorubicin + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + cyclophosphamide + doxorubicin + nab-paclitaxel.